| Name | Title | Contact Details |
|---|
Atenda Health Care Solutions is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company`s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex has also developed a blood volume monitor for use in hospitals and surgery centers.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
LED Dental traces its roots back to the mid-1990s, when company founder Peter Whitehead began performing oral cancer research in conjunction with the British Columbia Cancer Agency (BCCA). In 2000, Peter and a fellow BCCA researcher were awarded patents for groundbreaking technologies they developed for detecting oral cancer. Peter ultimately formed LED Medical Diagnostics Inc. and it operating subsidiary, LED Dental, to focus on the advancement of these technologies. LED Dental, in concert with the BCCA, ultimately co-developed the patented VELscope® Vx Enhanced Oral Assessment System, a tissue fluorescence visualization technology that received FDA and Health Canada clearance in 2006. Since then, there have been more than 12,000 VELscope Vx systems sold globally, and they have been used to perform more than 25 million oral examinations worldwide. In early 2014, LED Dental entered the dental imaging market in response to the explosive growth in dental CAD/CAM and the shift away from film-based systems to faster, more efficient and higher quality digital imaging solutions. We serve a previously unmet market demand for "open architecture" digital imaging technologies and we are rapidly growing a comprehensive portfolio of state-of-the-art offerings to meet this demand. Guiding our growth is a management team comprised some of the best minds from both the clinical and business sides of the dental industry. Drawing upon their decades of collective experience, they are identifying target technologies and product lines for our portfolio; building and managing our operations and sales teams; and developing a streamlined chain of communication that enables us to listen closely and serve the needs of our customers - and, in turn, enabling these clients to best serve their patients.